Skip to main content
Premium Trial:

Request an Annual Quote

EchelonDx, Oncocyte to Develop Software Supporting Commercial Diagnostics Expansion

NEW YORK – Healthcare informatics firm Echelon Diagnostics said Tuesday that it is collaborating with oncology diagnostic developer Oncocyte to develop analytical software that can scale to support the commercial expansion of Oncocyte's tests.

Based in Reno, Nevada, Echelon provides AI imaging and big data solutions supporting a range of molecular diagnostic technologies.

Irvine, California-based Oncocyte has built a pipeline of oncology diagnostic assays through acquisitions of various other companies and IP. Its first commercial offering, DetermaRx, is a 14-gene, RNA-based assay designed to identify patients with early-stage, non-small cell lung cancer who may benefit from adjuvant chemotherapy.

"EchelonDx was the right partner to help us build the software solution that allows us to scale and launch our proprietary tests worldwide in a manner that ensures … uniform and accurate testing," Oncocyte CSO Doug Ross said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.